Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Adma Biologics (ADMA) over the last 10 years, with Q1 2025 value amounting to $1.7 million.

  • Adma Biologics' Gains from Investment Securities changed N/A to $1.7 million in Q1 2025 from the same period last year, while for Mar 2025 it was $1.7 million, marking a year-over-year increase of 2359225.71%. This contributed to the annual value of $17000.0 for FY2023, which is 9857.63% down from last year.
  • According to the latest figures from Q1 2025, Adma Biologics' Gains from Investment Securities is $1.7 million.
  • In the past 5 years, Adma Biologics' Gains from Investment Securities registered a high of $1.7 million during Q1 2025, and its lowest value of $1000.0 during Q4 2023.
  • For the 4-year period, Adma Biologics' Gains from Investment Securities averaged around $264845.7, with its median value being $8830.0 (2022).
  • Over the last 5 years, Adma Biologics' Gains from Investment Securities had its largest YoY gain of 2434.64% in 2021, and its largest YoY loss of 9987.54% in 2021.
  • Quarter analysis of 4 years shows Adma Biologics' Gains from Investment Securities stood at $8493.0 in 2021, then grew by 2.66% to $8719.0 in 2022, then plummeted by 88.53% to $1000.0 in 2023, then soared by 165745.8% to $1.7 million in 2025.
  • Its Gains from Investment Securities stands at $1.7 million for Q1 2025, versus $1000.0 for Q4 2023 and $6000.0 for Q2 2023.